XOMA Royalty (XOMA) Asset Writedowns and Impairment (2012 - 2020)
XOMA Royalty (XOMA) reported Asset Writedowns and Impairment of -$1.4 million for Q4 2020, down 199.36% sequentially from $1.4 million in Q1 2020.
XOMA Royalty (XOMA) Asset Writedowns and Impairment (2012 - 2020) Analysis & Trends
XOMA Royalty (XOMA) has 2 years of Asset Writedowns and Impairment data on file, last reported at -$1.4 million in Q4 2020.
- For the quarter ending Q4 2020, Asset Writedowns and Impairment changed N/A year-over-year to -$1.4 million; the trailing twelve-month figure through Dec 2020 stood at $9000.0 (changed N/A YoY), and the FY2023 full-year result was $14.3 million, changed N/A from the prior year.
- Asset Writedowns and Impairment eased to -$1.4 million in Q4 2020, from $1.4 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 million in Q1 2020 to a low of -$1.4 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -1.40 Mn |
| Dec 31, 2020 | -1.40 Mn |
| Mar 31, 2020 | 1.41 Mn |
| Mar 31, 2020 | 1.41 Mn |
| Dec 31, 2012 | 219,000.00 |
| Dec 31, 2012 | 219,000.00 |
| Sep 30, 2012 | 160,000.00 |
| Sep 30, 2012 | 160,000.00 |
| Jun 30, 2012 | 374,000.00 |
| Jun 30, 2012 | 374,000.00 |
| Mar 31, 2012 | 1.71 Mn |
| Mar 31, 2012 | 1.71 Mn |